| |
original article |
Date |
Title |
Authors Max. 6 Authors |
| 1 |
[GO] |
2021―Nov―26 |
Baricitinib + remdesivir cost saving vs remdesivir for hospitalised COVID-19 patients in the USA |
|
| 2 |
[GO] |
2021―Nov―12 |
NZ's Pharmac negotiates deal for Roche's monoclonal antibodies for COVID-19 |
|
| 3 |
[GO] |
2021―Nov―12 |
NZ's Pharmac to fund baricitinib for moderate-to-severe COVID-19 |
|
| 4 |
[GO] |
2021―Nov―12 |
Counting the cost of COVID-19 at the peak of the pandemic in Spain |
|
| 5 |
[GO] |
2021―Nov―12 |
Baricitinib + SOC cost effective vs SOC for patients hospitalised with COVID-19 in the USA |
|
| 6 |
[GO] |
2021―Nov―12 |
Remote pulse-ox monitoring for COVID-19 patients saves costs, improves outcomes in the USA |
|
| 7 |
[GO] |
2021―Oct―29 |
Productivity losses impact cost effectiveness of COVID-19 vaccine |
|
| 8 |
[GO] |
2021―Oct―16 |
COVID-19 a substantial burden for hospitals and patients in the USA |
|
| 9 |
[GO] |
2021―Oct―16 |
NZ's Pharmac negotiates deal for molnupiravir to treat COVID-19 |
|
| 10 |
[GO] |
2021―Oct―16 |
UK's NICE updates COVID-19 guideline to include monoclonal antibody recommendations |
|
| 11 |
[GO] |
2021―Oct―16 |
Testing and restrictions are cost-effective COVID-19 measures |
|
| 12 |
[GO] |
2021―Oct―16 |
Estimated direct costs of COVID-19 pandemic high in Turkey, but true costs "undoubtedly higher" |
|
| 13 |
[GO] |
2021―Oct―16 |
Payments ≥$US500 would incentivise 50% of US people uncertain about COVID-19 vaccination |
|
| 14 |
[GO] |
2021―Oct―01 |
NZ's Pharmac to fund tocilizumab for moderate-to-severe cases of COVID-19 |
|
| 15 |
[GO] |
2021―Sep―03 |
Remdesivir may be cost saving in eligible patients during COVID-19 infections in Germany |
|
| 16 |
[GO] |
2021―Sep―03 |
ICER publishes draft scoping report on COVID-19 treatments |
|
| 17 |
[GO] |
2021―Aug―20 |
Remdesivir appears to save costs in COVID-19 patients on low-flow oxygen therapy in Turkey |
|
| 18 |
[GO] |
2021―Aug―07 |
UK's NICE issues guideline on diagnosing rare COVID-19 vaccination-related blood clots |
|
| 19 |
[GO] |
2021―Jul―23 |
NICE to publish guidelines for rare blood clotting syndrome from COVID-19 vaccination |
|
| 20 |
[GO] |
2021―Jul―10 |
COVID-19 lockdown increased diabetic mortality, morbidity and costs in Italy |
|
| 21 |
[GO] |
2021―Jul―10 |
Costs of ICU care during COVID-19 pandemic in USA |
|
| 22 |
[GO] |
2021―Jul―10 |
Best COVID-19 vaccine allocation strategy using a net-monetary benefit approach? |
|
| 23 |
[GO] |
2021―Jul―10 |
COVID-19-related decreases in paediatric PCV 13 use does not justify vaccination of older adults |
|
| 24 |
[GO] |
2021―Jun―26 |
Pfizer COVID-19 vaccine recommended for pregnant women in Australia and New Zealand |
|
| 25 |
[GO] |
2021―Jun―11 |
COVID-19 pandemic associated with substantial costs in older Medicare beneficiaries |
|
| 26 |
[GO] |
2021―Jun―11 |
Economic impact of avoidable cancer deaths due to COVID-19 pandemic 'substantial' |
|
| 27 |
[GO] |
2021―May―28 |
Expediting COVID-19 vaccination increases QALYs and saves costs in the USA |
|
| 28 |
[GO] |
2021―May―28 |
Tocilizumab cost effective in reducing COVID-19-related deaths |
|
| 29 |
[GO] |
2021―Apr―30 |
Remdesivir cost effective for severe COVID-19 in China |
|
| 30 |
[GO] |
2021―Apr―30 |
NICE COVID-19 rapid guidelines |
|
| 31 |
[GO] |
2021―Apr―16 |
COVID-19 QALY values differ between US EQ-5D-5L value sets |
|
| 32 |
[GO] |
2021―Apr―16 |
Easing of COVID-19 social restrictions in England comes at a cost |
|
| 33 |
[GO] |
2021―Apr―02 |
Willingness to pay for COVID-19 vaccination in China |
|
| 34 |
[GO] |
2021―Apr―02 |
Predicted uptake of COVID-19 vaccination in USA |
|
| 35 |
[GO] |
2021―Mar―19 |
Cost-effectiveness framework for evaluating COVID-19 therapies |
|
| 36 |
[GO] |
2021―Mar―19 |
Universal COVID-19 vaccination cost saving unless anaphylaxis rate high |
|
| 37 |
[GO] |
2021―Mar―19 |
Home-based rapid SARS-CoV-2 antigen testing reduces transmission, saves lives at reasonable cost |
|
| 38 |
[GO] |
2021―Mar―19 |
Australians willing to accept short-term restrictions during pandemic |
|
| 39 |
[GO] |
2021―Mar―05 |
Rapid COVID-19 movement restrictions reduce societal costs |
|
| 40 |
[GO] |
2021―Mar―05 |
WTP for COVID-19 vaccine in Chile |
|
| 41 |
[GO] |
2021―Feb―05 |
COVID-19 vaccination predicted to be cost effective in USA |
|
| 42 |
[GO] |
2021―Jan―22 |
ICU bed reserve capacity for COVID-19 cost effective in Germany |
|
| 43 |
[GO] |
2021―Jan―22 |
SARS-CoV-2 testing with saliva versus nasopharyngeal swabs: similar sensitivity, lower cost |
|
| 44 |
[GO] |
2021―Jan―08 |
Effects on LOS may not justify cost of remdesivir for severe COVID-19 |
|
| 45 |
[GO] |
2021―Jan―08 |
Cost effective COVID-19 mitigation measures in US colleges |
|
| 46 |
[GO] |
2021―Jan―08 |
Public's willingness to wait for COVID-19 vaccine |
|
| 47 |
[GO] |
2021―Jan―08 |
National lockdown not cost effective in Israel during COVID-2 pandemic |
|
| 48 |
[GO] |
2020―Nov―27 |
ICER's second update to pricing models of remdesivir for COVID-19 |
|
| 49 |
[GO] |
2020―Nov―27 |
COVID-19 control strategies cost effective in South Africa |
|
| 50 |
[GO] |
2020―Oct―30 |
Factors affecting COVID-19 vaccine acceptability in the US |
|
| 51 |
[GO] |
2020―Oct―30 |
Early, effective response to COVID-19 will reduce large resource needs |
|
| 52 |
[GO] |
2020―Oct―16 |
HTA assessment of COVID-19 interventions in Ireland |
|
| 53 |
[GO] |
2020―Oct―02 |
Expanded testing for COVID-19 could be cost effective in USA |
|
| 54 |
[GO] |
2020―Oct―02 |
Costs of active COVID-19 testing in Canada |
|
| 55 |
[GO] |
2020―Aug―21 |
Cost-benefit of COVID-19 lockdown in the UK |
|
| 56 |
[GO] |
2020―Jul―24 |
Willingness to pay for a COVID-19 vaccine high in Chile |
|
| 57 |
[GO] |
2020―Jul―10 |
ICER update to pricing models of remdesivir for COVID-19 |
|
| 58 |
[GO] |
2020―Jul―10 |
Policy options discussed for pricing novel COVID-19 vaccines/treatment |
|
| 59 |
[GO] |
2020―Jun―26 |
OOP burden for COVID-19-like respiratory hospitalisations varies in US |
|
| 60 |
[GO] |
2020―May―16 |
Impact of COVID-19 pandemic on HTA |
|
| 61 |
[GO] |
2020―May―16 |
COVID-19 testing before endoscopy safe, effective in the US |
|
| 62 |
[GO] |
2020―May―16 |
ICER releases pricing models for potential COVID-19 treatments |
|
| 63 |
[GO] |
2020―May―16 |
Demand for potentially hazardous COVID-19 treatments |
|
| 64 |
[GO] |
2020―May―03 |
Costs vs benefits of tackling COVID-19 |
|
| 65 |
[GO] |
2020―May―03 |
Substantial direct medical costs for symptomatic COVID-19 cases in the US |
|
| 66 |
[GO] |
2020―Apr―03 |
ICER's timelines for assessments extended due to COVID-19 |
|
